Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis1

Abstract

Use of CAM in children with steady-state bronchiectasis results in laboratory improvement by reducing the inflammatory processes in the lungs. No corresponding clinical improvement could be shown but although this is possible with long-term use, trial validation is necessary.